HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E1757 Gunagratinib Gunagratinib (ICP-192) is a pan-FGFR (fibroblast growth factor receptors) inhibitor with IC50 of 1.4, 1.5, 2.4 and 3.5 nM for FGFR1-4, respectively. It has the potential to treat advanced solid tumors. Feb 09 2025
E5825 Z-VAD Z-VAD is a competitive, irreversible pan-caspase inhibitor with broad specificity and weakly inhibits caspase-2. It induces autophagy and necrosis in irradiated breast and lung cancer models. Feb 09 2025
E6020 (±)-Darifenacin Darifenacin [(±)-UK-88525] is a potent, specific and competitive M3 selective receptor antagonist (M3 SRA) that has been shown to have high affinity and selectivity for the M3 receptor. It significantly improves major overactive bladder (OAB) symptoms with proven efficacy, tolerability, and safety. Jan 23 2025
E5836 ATX968 ATX968 (DHX9-IN-2) is a potent, selective, and orally bioavailable inhibitor of DHX9 helicase with an IC50 of 8 nM. It induces strong and sustained tumor growth inhibition or regression in MSI-H/dMMR colorectal cancer (CRC) xenograft models. Jan 23 2025
E5813 JNJ-28583113 JNJ-28583113 is a potent, brain-penetrant antagonist of TRPM2 with an IC50 of 126 nM that protects cells from oxidative stress-induced death and morphological changes. It also inhibits microglial cytokine release in response to pro-inflammatory stimuli and promotes GSK3α/β phosphorylation. Jan 23 2025
E4875 Lodoxamide Lodoxamide (U-42585E free acid) is a potent agonist of GPR35 with an EC50 of 1 nM. It also inhibits eosinophil peroxidase release after IgA activation and reduces eosinophil cationic protein and eosinophil-derived neurotoxin, suggesting direct effects on eosinophils. It is a mast cell stabilizer used to treat asthma, allergic conjunctivitis, and superior limbic keratoconjunctivitis. Jan 22 2025
E5841 Acetyl phosphate(lithium potassium) Acetyl phosphate(lithium potassium) is an endogenous metabolite, bypasses the LytS membrane potential sensor by phosphorylating LytR twice as fast, influencing lrgAB operon regulation in glucose-rich conditions without membrane potential disruption. Lithium potassium acetyl phosphate is studied for its electrochemical properties and role in phosphorus chemistry, with potential applications in lithium-ion battery technology and catalytic processes. Jan 22 2025
E1682 Tinlorafenib Tinlorafenib (PF-07284890, ARRY-461) is a potent, brain-penetrant inhibitor of BRAF targeting V600E/V600K mutations with IC50 values of 4.25 nM and 2.7 nM, respectively. It also effectively inhibits ERK phosphorylation and represents a new class of selective BRAF inhibitors for brain tumors. Jan 20 2025
E6045 2'-C-Methylcytidine 2'-C-Methylcytidine (NM107) is a potent and selective inhibitor of Chronic hepatitis C virus (HCV) NS5B polymerase with an EC50 of 1.85 μM in wild-type replicon cells. It also effectively inhibits foot-and-mouth disease virus(FMDV) replication with an EC50 of 6.4 μM. Therefore it is a potent antiviral that targets both viral and host factors, making it a promising option for HCV therapy and a potential prophylactic or therapeutic agent against FMDV outbreaks. Jan 20 2025
E4952 Nefazodone Nefazodone is a selective antagonist of 5-HT2Areceptors and moderately inhibits serotonin and norepinephrine reuptake, enhancing 5-HT synaptic transmission. It is also a potent inhibitor of CYP3A4 with reduced anticholinergic, alpha-adrenolytic, and sedative effects, along with notable immunoprotective properties. Jan 20 2025
S6992 Calcium chloride Calcium chloride (CaCl2) is an ionic compound used for calcium supplementation in conditions like hypocalcemia and hyperkalemia and as an antidote for magnesium toxicity. It also functions as a co-adjuvant in hemostatic formulations and effectively treats refractory hypotension and complete heart block. It enhances the activity of MoPtc1 and MoPtc2, type 2C protein phosphatases involved in the ionic stress response and MAPK signalling regulation in Magnaporthe oryzae. It can also be used as a desiccant and dehydrating agent. Jan 20 2025
E1422 (+)-JNJ-A07 (+)-JNJ-A07 is a highly potent inhibitor of Dengue virus (DENV) with an EC50 of 0.1 nM in the DENV-2 strain (16681) in Vero cells. It exhibits antiviral activity by preventing the formation of the viral replication complex through blocking the interaction between two viral proteins, NS3 and NS4B. Jan 16 2025
E1561 Obicetrapib Obicetrapib (TA-8995, AMG-899, DEZ-001) is an inhibitor of Cholesteryl Ester Transfer Protein (CETP) that significantly reduces non-HDL cholesterol (non-HDL-C) and lipoprotein(a) levels while increasing high-density lipoprotein cholesterol (HDL-C). It also has the potential to reduce major adverse cardiovascular events. Jan 16 2025
E1994 DBr-1 DBr-1 is a DCAF1-BRD9 PROTAC, created by linking the BRD9 binder BI-956448 to the DCAF1 scaffold via a piperidine-aliphatic carbon linker. It is a potent and selective degrader of BRD9 with a DC50 of 90 nM. It overcomes intrinsic resistance to VHL-degraders, positioning DCAF1-PROTACs as a promising strategy to counter ligase-mediated resistance. Jan 15 2025
A2168 Anti-human CD3 (UCHT1)-InVivo Anti-human CD3 (UCHT1)-InVivo reacts with human CD3ε a 20 kDa transmembrane cell-surface protein that belongs to the immunoglobulin superfamily Jan 14 2025
A4000 Amivantamab (Anti-cMet & EGFR) Amivantamab is a fully human bispecific antibody that targets both epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It exhibits immune anticancer activity in non-small cell lung cancer (NSCLC). MW :145.88 KD. Jan 13 2025
E1976 BAY-593 BAY-593 is an in vivo probe and small molecule inhibitor of geranylgeranyltransferase-I (GGTase-I), blocking oncogenic YAP1/TAZ. It exhibits potent anti-tumor activity and inhibits cancer cell proliferation in vitro. Jan 13 2025
E4798 SRI-011381 hydrochloride SRI-011381 hydrochloride is an agonist of the transforming growth factor-beta (TGF-β) signalling pathway and exhibits neuroprotective effects with the potential to treat Alzheimer's disease. It also increases fibronectin expression in the NIH‐3T3 cells stimulated by metformin. Jan 12 2025
E6046 phentolamine hydrochloride Phentolamine hydrochloride is a potent, selective, and orally active antagonist of α1 and α2 adrenergic receptors , with pKi values of 8.8, 8.0, and 8.3 for the human α2A, α2B, and α2C adrenergic receptors, respectively. It also shows binding affinities for the α1-adrenoceptor subtypes, exhibiting Ki values of 6.1 nM for cloned α1A/D, 39.8 nM for α1B, and 2.8 nM for α1C. Jan 12 2025
E4772 LDHA-IN-3 LDHA-IN-3, a selenobenzene derivative, is a potent noncompetitive inhibitor of Lactate Dehydrogenase A (LDHA), with an IC50 of 145.2 nM. It exhibits significant anti-tumor activity, effectively reducing LDHA activity and lactate production under both normoxic and hypoxic conditions. It also induces mitochondria-mediated apoptosis through the generation of reactive oxygen species. Jan 12 2025